Therapeutic targeting of CD36 after intracerebral hemorrhage
Therapeutic targeting of CD36 after intracerebral hemorrhage
批准号:
8303510
负责人:
KRISHNAN M. DHANDAPANI
金额:
$18.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-03-01 至 2014-02-28
关键词:
AccountingAcuteAddressAmericanBiochemicalBlood ClotBlood VesselsBlood coagulationBrainBrain hemorrhageCCAAT-Enhancer-Binding ProteinsCD36 geneCerebral hemisphere hemorrhageClinicalClinical ManagementCoagulation ProcessCurcuminDataDeteriorationDevelopmentDiabetes MellitusDoseErythrocytesGeneticGoalsHematomaHemorrhageHumanHypertensionIncidenceInterventionKnowledgeLaboratoriesLesionLocationMediatingMediator of activation proteinMedicalMicrogliaModelingMolecularMolecular WeightMorbidity - disease rateMusNervous System TraumaNeurologicNeurological outcomeOperative Surgical ProceduresOutcomePathway interactionsPatientsPatternPhagocytosisPharmacologic SubstanceResearchResolutionRisk FactorsRodentRoleRuptureSR-B proteinsSerumSpicesStrokeTestingTherapeuticaging populationbasebrain tissueclinical careclinical practicedemographicsimprovedmortalityneuroimagingnovelnovel therapeuticspre-clinicaltherapeutic targettranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Intracerebral hemorrhage (ICH), the most common form of hemorrhagic stroke, accounts for up to 15% of all strokes, with 37,000-52,400 Americans suffering an ICH annually. ICH has the highest acute mortality and the worst long-term neurological outcomes of all types of stroke. ICH is caused by a ruptured blood vessel within the brain, leading to the formation of a space occupying hematoma. Hematoma volume is clinically associated with neurological deterioration and higher mortality; however, many ICH patients are poor surgical candidates and/or present with an unfavorable size/location of the lesion, restricting the utility of neurosurgical intervention. Furthermore, efficacious medical treatment options to promote hematoma clearance are lacking, presenting a critical barrier to clinical practice. Our long-term objective is to identify the molecular and cellular pathways which
contribute to clot resolution after ICH. This knowledge will provide a framework for pharmaceutical development to improve patient outcomes after ICH. Our pilot data suggest the curry spice, curcumin, promotes hematoma resolution after ICH and may therefore represent a novel and safe treatment option. Specific Aim 1 will test the hypothesis that CD36 mediates curcumin-induced hematoma clearance after ICH. Specific Aim 2 will test the hypothesis that C/EBP-¿ mediates curcumin-induced CD36 expression and hematoma resolution after ICH. Together, the proposed studies will elucidate the molecular and cellular mechanisms which underlie the ability of curcumin to promote hematoma resolution. The results of these studies will provide a framework for pharmaceutical development targeting C/EBP-¿ and/or CD36 to improve clinical outcomes after ICH.
PUBLIC HEALTH RELEVANCE: Intracerebral hemorrhage (ICH), the most common type of hemorrhage stroke, is induced by a ruptured blood vessel, resulting in the formation of a space-occupying hematoma (blood clot) within the brain. Hematoma volume is associated with increased patient mortality; however, few treatment options are available to eliminate the clot. Given that the rate of ICH incidence is expected to double over the next 50 years as a result of an aging population and increased risk factors (e.g. hypertension, diabetes), novel therapeutic strategies to promote hematoma resolution are needed. The present application will assess the potential for the clinically non-toxic curry spice, curcumin, to promote hematoma resolution and improve outcomes after ICH.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunometabolic regulation after CNS injury
-
批准号:10737334
-
项目类别:
-
资助金额:$197.53万
-
财政年份:2023
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
Augusta SPAN 2
-
批准号:10591250
-
项目类别:
-
资助金额:$61.6万
-
财政年份:2023
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
-
批准号:10240740
-
项目类别:
-
资助金额:$38.09万
-
财政年份:2020
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
-
批准号:10676330
-
项目类别:
-
资助金额:$38.09万
-
财政年份:2020
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
-
批准号:10459588
-
项目类别:
-
资助金额:$38.09万
-
财政年份:2020
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
Remote ischemic Conditioning Promotes Cerebrovascular Recovery after Intracerebral Hemorrhage
-
批准号:10035049
-
项目类别:
-
资助金额:$38.09万
-
财政年份:2020
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
NLRP3 inflammasome and TBI
-
批准号:8570673
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2013
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
NLRP3 inflammasome and TBI
-
批准号:8666092
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2013
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
Therapeutic targeting of CD36 after intracerebral hemorrhage
-
批准号:8432013
-
项目类别:
-
资助金额:$18.09万
-
财政年份:2012
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
HMGB1 and Traumatic Brain Injury
-
批准号:8525465
-
项目类别:
-
资助金额:$30.41万
-
财政年份:2009
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
HMGB1 and Traumatic Brain Injury
-
批准号:7792899
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2009
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
HMGB1 and Traumatic Brain Injury
-
批准号:8119453
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2009
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
HMGB1 and Traumatic Brain Injury
-
批准号:8316213
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2009
-
负责人:KRISHNAN M. DHANDAPANI
-
依托单位:
海外基金